Company: IMRX
Filing Date: 2025-09-24
Form Type: 8-K
Source: 0001104659-25-092957
Chunk: 0

Company: Immuneering Corp
Filing Date: 2025-09-24
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01. Entry Into a Material Definitive Agreement.

On September 24, 2025, Immuneering Corporation (the “ Company”)
entered into a securities purchase agreement (the “ Purchase Agreement”) with Aventis Inc. (the “ Investor”), a
wholly owned subsidiary of Sanofi, a French société anonyme, pursuant to which the Company, in a private placement transaction
(the “ Private Placement”), agreed to issue and sell to the Investor $25.0 million of shares (the “ Class A Shares”)
of the Company’s Class A common stock, par value $0.001 per share (“ Class A Common Stock”), or in certain circumstances
in lieu of Class A Shares, shares (the “ Class B Shares” and, together with the Class A Shares, collectively, the “ Shares”)
of the Company’s non-voting Class B common stock, par value $0.001 per share (“ Class B Common Stock”), subject to and
contingent upon the closing of a firm commitment underwritten public offering of Class A Common Stock by the Company that results in gross
proceeds to the Company of at least $75.0 million and the pricing of which is publicly announced in a press release issued by the Company
on or before September 26, 2025 (a “ Public Offering”). The price per Share will be the price per share of Class A Common Stock
to the public in the Public Offering as set forth on the cover of the definitive prospectus related to the Public Offering. To the extent
any Class B Shares are issued and sold in the Private Placement, the conversion of such Class B Shares into shares of Class A Common Stock
will be subject to the Beneficial Ownership Limitation (as defined below). The Company does not intend to list the Class B Common Stock
on The Nasdaq Global Market (“ Nasdaq”) or any other nationally recognized securities exchange or trading system.

The closing of the Private Placement is contingent upon the closing
of a Public Offering and is expected to occur substantially concurrently with the closing of such Public Offering, subject to the satisfaction
of customary closing conditions.

Pursuant to the Purchase Agreement, the Company also agreed to (i)
notify the Investor within three business days of the Company engaging in discussions with any third party regarding, or the Company’s
board of directors authorizing the Company to pursue or initiate a process to pursue, any transaction that would be reasonably expected
to result in a change of control of the Company